Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Porfimer Sodium PDT and Stent Placement in Unresectable Cholangiocarcinoma
NCT00253617Phase 3Withdrawn
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of porfimer sodium in cholangiocarcinoma (CCA) (2 arms), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Overall Survival. Status: withdrawn.
02
Drugs
porfimer sodium
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT00253617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00253617.